CHANGING THE ALZHEIMER'S GAME, PERIOD
Make no mistake, the recently developed protocol known as the perispinal injection administration route of drug delivery is nothing short of a game changer in neurology, allowing for peripheral, non-invasive delivery of such compounds to penetrate the CNS.
The area in which the injection is performed (known as vertebral venous plexus), is a bi-directional system; it can be conceptualized as an interface between the peripheral lymphatic system and the ventricular system in the CNS.
A single injection of etanercept, for example, into the vertebral venous plexus followed by a maneuver (similar to a session in the popular relaxation device known as the inversion chair) called Trendelenburg positioning directs the compound through the choroid plexus and into the ventricles.
Therefore, this injection, which is subcutaneous and performed peripherally, is non-invasive, most importantly, it has been shown to thwart the “first domino” in a plethora of Neurodegenerative (Dementias stemming from a variety of neurodegenerative conditions including Alzheimer's Disease, Pick’s Disease, Lewy Body Disease), Neurotraumatic (Traumatic Brain Injury [TBI], and the sequelae of repeated TBI incidents such as Chronic Traumatic Encephalopathy or CTE. CTE is a degenerative condition linked to repeated head injuries), and Neuropsychiatric Pathologies (including chronic pain syndrome, neuropathies [including diabetic neuropathy]mood disorders such as Major Depressive Disorder [MDD]) and most recently opioid dependence.
In the CNS, the ventricles intimately communicate with the brain parenchyma. The fact that compounds delivered via this route have been shown to reach neurons in the CNS and exert an effect on neuronal functioning demonstrates/indicates how (PERIPHERAL) administration of a ligand known to be incapable of Blood-Brain-Barrier penetration, generates a signal, which is neuronally communicated throughout the brain parenchyma (CNS)
Perhaps the single most exciting examples of these developments can be found in the amazing research and clinical work by Edward Tobinick, Robert Spengler, Tracey Ignatowski and their colleagues.
Latest September 1st Should be Available
LATEST NY TIMES UPDATES (Thursday, September 1st 2016 9:30 AM EST) on NY Times Discussion on Impact of Perispinal Etanercept Administration on Clinical Course of Alzheimer's Disease.
Confirmation of the research results and clinical outcomes reported by Robert Spengler, Tracey Ignatowski and Edward Tobinick and colleagues showing positive effects on a plethora of Neurodegenerative/Neuroinflammatory conditions.
New evidence shows properties of etanercept result in significantly reduced rates of Alzheimer's Disease (AD) in Rheumatoid Arthritis (RA) patients compared to every other FDA approved RA treatment.
Gerald Hecht, 2016. Unauthorized use and/or duplication of this material without express and written permission from this author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Gerald Hecht with appropriate and specific direction to the original content.